Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach

International Journal of Drug Policy

Volumn 18, Issue 5, 2007, Pages 417-425

  Birkhead, Guthrie S ^a,b   Klein, Susan J ^a   Candelas, Alma R ^a   O'Connell, Daniel A ^a   Rothman, Jeffrey R ^a   Feldman, Ira S ^a   Tsui, Dennis S ^a   Cotroneo, Richard A ^a   Flanigan, Colleen A ^a  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

HCV; Hepatitis C virus; IDU; Injection drug use; Prevention

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMMUNITY CARE; DRUG USE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SERVICE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAID; MEDICAL EDUCATION; PERIODIC MEDICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SUBSTANCE ABUSE; SUPERINFECTION; SYRINGE;

COMMUNITY HEALTH SERVICES; COMMUNITY PHARMACY SERVICES; HARM REDUCTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICAID; MEDICAL WASTE DISPOSAL; MEDICALLY UNINSURED; MODELS, ORGANIZATIONAL; NEEDLE-EXCHANGE PROGRAMS; NEW YORK; PATIENT EDUCATION; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PRISONERS; PROGRAM DEVELOPMENT; QUALITY OF HEALTH CARE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34548507230     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.01.013     Document Type: Article

References (48)

1. Alter M., and Moyer L. The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18 Suppl. 1 (1998) S6-S10
2. Armstrong G., Wasley A., Simard E., McQuillan G., Kuhnert W., and Alter M. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 144 10 (2006) 705-714
3. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 1 (2001) 188-193
4. Backmund M., Reimer J., Meyer K., Gerlach J.T., and Zachoval R. Hepatitis C virus infection and injection drug users: Prevention, risk factors and treatment. Clinical Infectious Diseases 40 Suppl. 5 (2005) S330-S335
5. Battles H.B., Tesoriero J.M., Heavner K.K., Birkhead G.S., and Klein S.J. Evaluation of a public-private partnership for syringe access and safe disposal. XVI international AIDS conference. Toronto, Canada, August 13-18 (2006). http://www.iasociety.org/abstract/show.asp?abstract_id=2181753 Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=2181753 Accessed August 14, 2006 (Abstract No. THPE0880)
6. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., et al. Increasing mortality due to end-stage liver disease in patients with Human Immunodeficiency Virus infection. Clinical Infectious Diseases 32 (2001) 492-497
7. Candelas, A.R. (1997). USA New York State promotes the harm reduction approach. AIDS/STD health promotion exchange, 2. Available at: http://www.kit.nl/frameset.asp?/ils/exchange_content/html/index_country. asp&frnr=1&.
8. Crofts N., Caruana S., Bowden S., and Kerger M. Minimizing harm from hepatitis C virus needs better strategies. British Medical Journal 321 (2000) 899
9. Davis G., and Rodrigue J. Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine 345 3 (2001) 215-217
10. Deren S., Fuller C., Pouget E.R., Blaney S., Tortu S., Kang S.Y., et al. Impact of expanding syringe access in New York on sources of syringes for injection drug users in Harlem and the Bronx, NYC, USA. International Journal of Drug Policy 14 (2003) 373-379
11. Des Jarlais D.C., Marmor M., Paone D., Titus S., Shi Q., Perlis T., et al. HIV incidence among injecting drug users in New York City syringe-exchange programs. The Lancet 348 (1996) 987-991
12. Des Jarlais D.C., Paone D., Marmor M., Titus S., Sotheran J.L., and Friedman S.R. New York City syringe evaluation: The New York City syringe exchange program: Evaluation of a public health initiative. Presented at the conference of the American Public Health Association. Washington, DC (1994, November)
13. Des Jarlais D., Perlis T., Arasteh K., Torian L., Hagan H., Beatrice S., et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 19 Suppl. 3 (2005) S20-S25
14. Edlin, B. R. (2002). Prevention and treatment of hepatitis C in injection drug users. Hepatology, 36(5)(Suppl. 1), S210-S219.
15. Edlin B.R., and Carden M.R. Injection drug users: The overlooked core of the hepatitis C epidemic. Clinical Infectious Diseases 42 (2006) 673-676
16. Edlin B.R., Kresina T.F., Raymond D.B., Carden M.R., Gourevitch M.N., Rich J.D., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in injection drug users. Clinical Infectious Diseases 40 Suppl. 5 (2005) S276-S285
17. Hagan H., and Des Jarlais D.C. HIV and HCV infection among injecting drug users. The Mount Sinai Journal of Medicine 67 5-6 (2000) 423-428
18. Hagan H., Latka M.H., Campbell J., Golub E.T., Garfein R.S., Thomas D.A., et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 U.S. cities. Clinical Infectious Diseases 42 (2006) 669-672
19. Hagan H., Strauss S.M., Astone J.M., and Des Jarlais D.C. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clinical Infectious Diseases 40 Suppl. 5 (2005) S297-S303
20. Hagan H., Thiede H., Weiss N., Hopkins S., Duchin J., and Alexander E. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91 (2001) 42-46
21. Klein S.J., Birkhead G.S., and Candelas A.R. Commentary: Expanded Syringe Access Demonstration Program (ESAP) in New York State (NYS): An intervention to prevent HIV transmission. Journal of Urban Health 77 4 (2000) 762-767
22. Klein S.J., Estel G.R., Candelas A.R., and Plavin H.A. Promoting safe syringe disposal goes "hand in hand" with expanded syringe access in New York State. Journal of the American Pharmaceutical Association 42 Suppl. 2 (2002) 105-107
23. Klein, S. J., Wright, L. N., Birkhead, G. S., Mojica, B. A., Klopf, L. C., Klein, L. A., et al. (in press). Promoting HCV treatment completion for prison inmates: New York State's Hepatitis C Continuity Program. Public Health Reports.
24. Litwin A., Soloway I., and Gourevitch M.N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases 40 Suppl. 5 (2005) S339-S345
25. Munoz-Plaza C.E., Strauss S.M., Astone J.M., Des Jarlais D.C., and Hagan H. Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. The Journal of Drug Issues Fall (2004) 861-878
26. National Institutes of Health (NIH). (2002). NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state-of-the-science statements, 19(3). Available at: http://consensus.nih.gov/2002/2002HepatitisC2002116PDF.pdf Accessed January 23, 2006.
27. New York State Department of Correctional Services. HUB system: Profile of inmate population under custody on January 1, 2004 (2005), NYSDOCS, Albany, NY
28. New York State Department of Health. (2004). Viral Hepatitis Strategic Plan, June 2004. Albany, NY: New York State Department of Health. Available at: http://www.health.state.ny.us/diseases/communicable/hepatitis/strategic/ index.htm Accessed July 19, 2006.
29. New York State Department of Health. (2005a). 2005 annual chronic hepatitis surveillance report. Available at: http://www.health.state.ny.us/diseases/communicable/hepatitis/docs/hbv_h epc_chronic_report_2005.pdf Accessed August 14, 2006.
30. New York State Department of Health. (2005b). Clinical guidelines for the management of hepatitis C, 2005. Albany, NY: New York State Department of Health. Available at: http://www.health.state.ny.us/diseases/communicable/hepatitis/guidelines /index.htm Accessed July 19, 2006.
31. New York State Department of Health. (2006). New York State HIV/AIDS surveillance semiannual report for cases diagnosed through December 2004, April 2006. Albany, NY: New York State Department of Health. Available at: http://www.health.state.ny.us/diseases/aids/statistics/semiannual/2004/s urveillance_semiannual_report_2004_december.pdf Accessed July 24, 2006.
32. New York State Department of Health, AIDS Institute, Office of the Medical Director. (2004). Hepatitis C virus. Available at: http://www.hivguidelines.org/GuideLine.aspx?pageID=257&guideLineID=1 7 Accessed August 8, 2006.
33. Pouget E.R., Deren S., Fuller C.M., Blaney S., McMahon J.M., Kanyg S.Y., et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. JAIDS 39 4 (2005) 471-477
34. Raymond D., Curry J., and Ellendon N. Addressing hepatitis C through HIV prevention services for injection drug users: Program development and policy considerations. The XV international AIDS conference, 2004. Bangkok, Thailand, July 11-16, 2004 (2004). http://www.iasociety.org/abstract/show.asp?abstract_id=2168920 Available at: http://www.iasociety.org/abstract/show.asp?abstract_id=2168920 Accessed August 21, 2006 (Abstract No. TuPeE5437)
35. Rothman, J. R., Birkhead, G., Rudnick, D., Slifer, M., Agins, B., & Heiner, K. (in press). Co-located substance use treatment and HIV prevention and primary care services; New York State, 1990-2002: A model for effective service delivery to a high risk population. Journal of Urban Health.
36. Serfaty L., Costagliola D., Wendum D., Picard O., Meyohas M., Girard P., et al. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: A case-control study. AIDS 15 (2001) 2011-2016
37. Stancliff, S., Agins, B., Rich, J. D., & Burris, S. (2003). Syringe access for the prevention of blood borne infections among injection drug users. BMC public health. Available at: http://www.biomedcentral.com/1471-2458/3/37 Accessed July 26, 2006.
38. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 4 (2004) 1147-1171
39. Sulkowski M.S., and Thomas D.L. Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. AIDS 19 Suppl. 3 (2005) S8-S12
40. Tesoriero J.M., Battles H.B., Heavner K.K., Knight-Coyle N., Birkhead G.S., and Klein S.J. Assessment of New York's Expanded Syringe Access Demonstration Program: Results from statewide baseline and follow-up surveys of physicians. Evidence based policy and practice: 133rd annual meeting of the American Public Health Association. Philadelphia, PA, December 10-14, 2005 (2005) (Poster Session 3245.0)
41. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institute on Drug Abuse and Substance Abuse and Mental Health Services Administration. (1997). HIV prevention bulletin: Medical advice for persons who inject illicit drugs. May 9, 1997. Available at: http://www.cdc.gov/idu/pubs/hiv_prev.htm Accessed July 25, 2006.
42. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity mortality weekly report, 47(RR-19), pp. 1-40.
43. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National hepatitis C prevention strategy (2001), U.S. Department of Health and Human Services, Atlanta, GA. http://www.cdc.gov/ncidod/diseases/hepatitis/spotlights/c_strategy.htm Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/spotlights/c_strategy.htm Accessed August 8, 2006
44. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2001b). Public health and injection drug use. Morbidity mortality weekly report, 50(19), p. 377.
45. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (2003). Prevention and control of infections with hepatitis viruses in correctional settings. Morbidity mortality weekly report, 52(RR-9), pp. 1-35.
46. Wodak A., and Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: A comprehensive review of international evidence. Substance Use & Misuse 41 (2006) 777-813
47. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 90 (2000) 1562-1569
48. Zingman B., Ortiz-Morales H., Freeman K., Rodriguez F., Meola C., Shuter J., et al. The Montefiore HIV/HCV co-infection program: 18-month results from an expert multidisciplinary team co-located at an urban HIV primary care clinic. The American Conference for the Treatment of HIV (ACTHIV). Atlanta, GA, September 15-18, 2005 (2005). http://www.ushivconference.org/media/pdf/posters/b_zingman.pdf Available at: http://www.ushivconference.org/media/pdf/posters/b_zingman.pdf Accessed August 21, 2006 (Poster Session)